Brief: Soligenix Announces Scheduling Of Type A Meeting With U.S. FDA
11/05/2023 12:46
May 11 (Reuters) - Soligenix Inc SNGX.O :
* SOLIGENIX ANNOUNCES SCHEDULING OF TYPE A MEETING WITH THE
U.S.
FDA TO REVIEW PROPOSED STUDY DESIGN FOR A SECOND PHASE 3 STUDY
EVALUATING HYBRYTE™ IN THE TREATMENT OF CUTANEOUS T-CELL
LYMPHOMA
* SOLIGENIX INC - UPDATE ON FDA MEETING OUTCOME EXPECTED
NEXT
MONTH
Source text for Eikon: ID:nPnc91KZKa
Further company coverage: SNGX.O
((Reuters.Briefs@thomsonreuters.com;))